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Abstract
Purpose The present study examines the role of Type D
personality, anxiety and depression in quality of life (QoL)
in patients with two chronic neurological diseases—Par-
kinson’s disease (PD) and multiple sclerosis (MS).
Methods This cross-sectional study included 142 PD
patients (73 % males; mean age 67.6 ± 9.2 years) and 198
patients with MS (32.3 % males; 38.4 ± 10.8 years).
Multiple regression analyses were used to analyze the
association of UDPRS (PD patients) or EDSS (MS
patients), Type D personality (DS-14) and anxiety and
depression (HADS) with the physical (PCS) and mental
summary (MCS) of QoL, as measured by the SF-36.
Results In PD patients, Type D was significantly associ-
ated with MCS only; in MS patients, Type D was signifi-
cantly associated with both dimensions—MCS and PCS.
After adding anxiety and depression, the importance of
Type D for the QoL model dramatically decreased. Anxiety
and depression were strongly associated with lower scores
in MCS and PCS in both PD and MS patients.
Conclusions The actual mood of PD and MS patients—
the level of anxiety or depression—might have a greater
impact on patients’ QoL than their personality. Further
longitudinal research should focus on how the pathway
consisting of personality traits, anxiety and depression, and
QoL might be constructed.
Keywords Parkinson’s disease  Multiple sclerosis 
Quality of life  Type D personality  Depression  Anxiety
Introduction
The major clinical symptoms of Parkinson’s disease (PD)
and multiple sclerosis (MS) significantly affect a patient’s
quality of life. Symptoms associated with PD are tremor,
rigidity, bradykinesia, and falls, as well as non-motor
symptoms like painful spasms, depression, sleep problems,
and fatigue [1, 2]. Multiple sclerosis (MS) is a disorder of
the central nervous system (brain and spinal cord) caused
by lesions in the white matter of the central nervous sys-
tem, which degenerate the myelin sheath. It is marked by
lack of muscle coordination, muscle weakness, speech
problems, paresthesia, and visual impairments [3, 4]. MS is
characterized by recurrent attacks of neurological symp-
toms followed by a remission [4]. Other forms of MS are
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secondary progressive, primary progressive, progressive
relapsing, and the malignant course of the disease [5]. In
both diseases, the symptoms lead to worse physical, mental
and social well-being in comparison with people of the same
age without symptoms of Parkinsonism or MS [2, 6–10].
Mood disorders, especially depression, are among the
clinical symptoms of both diseases. In PD patients, the
prevalence of depression ranges from 20 to 40 % [11, 12],
while depression affects 27–54 % of MS patients [13, 14].
Both diseases are often associated with higher scores in
anxiety [15, 16]. A recent study by Goretti et al. [17]
clearly presented that depression had a negative impact on
all QoL domains and anxiety on the mental domains in MS
patients. Anxiety and depression, even at moderate levels,
were also positively linked with poor QoL in studies about
PD [12, 18].
Other psychological factors have been identified as
important variables in QoL models. Personality traits,
mostly high levels of neuroticism and low levels of extra-
version, contributed to a worse perception of QoL in several
diseases [19–26]. The construct of the Type D personality
was primarily designed for measuring personality traits in
coronary heart disease patients associated with an increased
risk of depressive symptoms, a higher number of reinfarc-
tions and higher mortality rates [27, 28]. This personality
type refers to individuals who experience increased nega-
tive emotions and are inhibited in social interactions and is
composed of two dimensions—negative affectivity (NA)
and social inhibition (SI). NA is the tendency to experience
negative emotions like anger, dysphoria, irritability, hostile
feelings, depressed affect, and anxiety. SI is the tendency to
inhibit these emotions in social interactions [28]. Individ-
uals who achieve both a high NA score and a high SI score
could be labeled as having Type D personality and are
characterized by a fear of impending troubles and by
avoidance of negative reactions from others through
excessive control over self-expression [28–30]. In further
studies, its validity among non-cardiovascular diseases was
also shown. Type D was associated with poor physical and
mental health status among patients with melanoma, Par-
kinson’s disease, mild traumatic brain injury, vertigo
complaints, tinnitus or sleep apnea [31–33]. The DS-14
questionnaire, which measures Type D, was evaluated as a
valid instrument for assessing and comparing Type D per-
sonality across clinical groups as well [34].
In a previous study, we concluded that Type D per-
sonality plays an important role in QoL assessment in PD
patients. Having a Type D personality was, after disease
severity, the second most important determinant of overall
QoL and was related to the patient’s worse score in the
dimensions associated with mental status, as measured by
Parkinson’s Disease Questionnaire (PDQ-39) [32].
Neurologists should be aware of factors associated with a
patient’s QoL in order to be able to choose the most effective
interventions in the framework of treatment. For this study,
Type D personality, anxiety and depression were assumed to
be the variables associated with the perception of health
status and thus might lead to a worse perception of QoL
among patients with Parkinson’s disease and patients with
multiple sclerosis. The aim of this study is to explore whether
Type D was associated with the mental and physical health
status of quality of life in PD and MS patients even when
depression and anxiety are added to the model.
Methods
Participants and sample size
Patients with PD and MS in this cross-sectional study were
recruited from the databases of 4 hospitals and 17 outpa-
tient clinics and also from MS society in the eastern part of
the Slovakia between February 2004 and February 2006.
Neurologists from the mentioned institutions diagnosed all
patients included in the sample as suffering from PD
according to the United Kingdom Parkinson’s Disease
Society Brain Clinical Criteria [35]. MS patients were
diagnosed by neurologists according to the diagnostic cri-
teria for MS [4]. Data collection of MS patients took place
between December 2003 and July 2006.
Exclusion criteria for both diseases were defined as
follows: (a) patients with a Mini-Mental State Examination
(MMSE) score [36] below 23 points, (b) co-morbidities
and movement disabilities not caused by MS or PD.
Sociodemographic data were derived from question-
naires filled in by the patients themselves and data about
neurological treatment from their medical records. Dis-
ability in each patient was assessed by a neurologist. The
study was conducted after informed consent was obtained
from the patients prior to the interview. Participation in the
research was voluntary. The local Ethics Committee of the
University Hospital in Kosice approved the study in Kosice
on 17 December 2002.
Measures
Disease severity
Disease severity was measured using the Unified Parkin-
son’s Disease Rating Scale (UPDRS) in PD patients and
the Kurtzke Expanded Disability Status Scale (EDSS) in
MS patients. The UPDRS and EDSS remain the most
frequently used scoring systems in PD and MS neurologi-
cal practice.
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The UPDRS consists of four parts, pertaining to men-
tation and mood (Part 1), activities of daily living (Part 2),
motor function (Part 3), and complications of dopaminergic
therapy (Part 4), including motor fluctuations and dyski-
nesias. Parts 1, 2, and 4 are interview-based; Part 3 is based
on a clinical examination by a health care professional and
represents the patient’s condition at the time of the
examination. A neurologist can score patients from 0 to
176, where higher scores indicate increased disease
severity [37].
The EDSS is based on testing functional systems:
pyramidal, cerebellar, brainstem, sensory, bowel and
bladder, visual, mental, and ‘‘other.’’ Disability caused by
SM is graded on a continuum from 0 (normal neurological
examination) to 10 (death caused by MS) [38].
Type D personality
For assessing Type D personality, the DS-14 was used with
its constituent subscales, negative affectivity (NA) and
social inhibition (SI) [28]. Subjects rated these aspects of
their personality on a 5-point Likert scale ranging from
0 = false to 4 = true. The NA and SI scales were scored as
continuous variables (range 0–28). A cut-off of 10 on both
scales (NA C 10 and SI C 10) was used to classify sub-
jects as Type D [28]. Cronbach’s alpha in the original study
was 0.88 for NA and 0.86 for SI. In the current study, DS-
14 had good internal consistency in both diseases: Cron-
bach’s alpha in PD patients was .77 for NA and .76 for SI,
and for MS patients, it was .84 for NA and .83 for SI.
HADS
The fourteen-item Hospital Anxiety and Depression Scale
(HADS) was used for assessing anxiety and depression in
non-psychiatric hospital departments [39]. Seven items are
related to the depression and 7 to anxiety. Patients
responded on a 4-point scale (from 0 = absent to
3 = definitely present/severe). Scores ranged from 0 to 21
for each scale where a higher score implied more depres-
sion or anxiety. Cronbach’s alpha for depression was .79
for both MS and PD patients, and for anxiety, it was .81 for
MS and .69 for PD patients.
SF-36
The thirty-six item Short Form Health Survey (SF-36) was
designed to measure health-related quality of life
(HRQOL) from the patient’s point of view as part of the
Medical Outcome Study (MOS). It assesses 8 health con-
cepts: (a) physical functioning; (b) role limitations because
of physical health problems; (c) bodily pain; (d) general
health perception; (e) vitality (energy/fatigue); (f) social
functioning; (g) role limitations because of emotional
problems; and (h) general mental health [40]. These scales
are further combined into 2 scales: a physical component
summary score PCS (subscales a–d), which contains
information about physical health status (PHS), and a
mental component summary score (MCS) (subscales e–h),
which informs about mental health status (MHS). All item
scores are transformed into a scale from 0 (poor health) to
100 (optimal health) [41]. Cronbach’s alphas for the sum-
mary scores were .87 for PCS and .78 for MCS in PD
patients, and .89 for PCS and .89 MCS for patients with
MS.
Statistical analyses
Independent-sample t-tests were conducted to assess dif-
ferences between the sample of MS and PD patients in age,
disease duration, anxiety, depression, PCS and MCS. Also,
the difference of proportions test (CIA) was used for
assessing gender differences in partnership, Type D and
education [42]. Stepwise linear regression with forward
selection of variables was used to assess the contribution of
the independent variables in three models. This method
was chosen as a suitable tool for identifying predictor
variables of the physical and mental components of QoL. It
also captures changes that occur when additional variables
are added to the model. Dependent variables included the
PCS and MCS, while the independent variables were dis-
ease severity, disease duration, demographic data (gender,
age, and education), Type D personality, and anxiety and
depression. The first model included disease severity,
gender, age, education, and disease duration. In the second
model, Type D personality was added. The third model
also contained the variables anxiety and depression.
Data were analyzed using the software Statistical
Package for the Social Sciences (SPSS 16.0).
Results
Descriptive statistics
Out of 512 invited patients with Parkinson’s disease, 160
patients agreed to participate and filled in the question-
naires, but 7 patients were excluded after the personal
interview because of the exclusion criteria. The final sample
thus consisted of 153 patients (response rate 31.3 %). Non-
respondents were on average older compared with the
analyzed group in age (mean difference = 1.69 years,
SE = .87; t = -1.95; 95 % CI = .010–3.39), and there
were significantly more women than men among non-
respondents (difference = -0.0110; SE = .041; 95 %
CI = -.091–.069).
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From 412 MS patients who were asked to participate in the
study, 207 patients were interviewed (52 %) and 205 patients
did not respond. There were no statistically significant dif-
ferences between non-respondents and participants regard-
ing gender, disease duration, and clinical course of MS.
However, the non-respondents were on average older than
the participants (mean difference = 1.69 years, SE = .87;
t = -1.95; 95 % CI = .010–3.39).
Eleven patients with PD and nine patients with MS were
removed from the sample because of missing data. The study
ultimately involved 142 PD patients (73 % males; mean age
67.6 ± 9.2 years) and 198 patients with MS (32.3 % males;
38.4 ± 10.8). The majority of MS patients belonged to the
relapsing-remitting clinical course (RR-MS; 70.2 %).
All PD patients used antiparkinsonian therapy according
international guidelines [41, 42]. Fifty-six per cent of MS
patients in this study were being treated with interferon-
beta therapy (Table 1).
Disease severity, personality, depression and anxiety,
and quality of life
Three models were constructed to explore the contribution
to the variance of PCS and MCS.
In Model 1, which consisted of disease severity, gender,
age, education, and disease duration, worse disease severity
was associated with a worse score in mental and in physical
health status in PD patients, and female gender was asso-
ciated with a worse PCS, as well. Older age and more
serious disease severity were the main predictors of MCS
and PCS in MS patients (Table 2).
When Type D was added (Model 2), the strength of the
model increased for MCS and PCS in both diseases. In PD
patients, Type D was significantly associated with higher
score in both diseases in MCS only. Aside from disease
severity, which remained significantly associated with the
PCS domain in both diseases, age was the second most
important variable in the model of PCS in MS patients
associating only with a worse PCS score (Table 2).
Model 3 showed a further increase in explained variance
for both diseases, when the variables anxiety and depres-
sion were added (Model 3). Anxiety and depression were
strongly associated with lower scores in both subscales of
the SF-36 in both groups of patients, except in the PCS
domain in MS patients. Disease severity remained signifi-
cantly associated in the PCS domain in both diseases,
which means that a worse score in the disease severity
scales leads to a worse perception of health status.
Table 1 Characteristics of the
sample—means and standard
deviations (SD) or N (%) on
demographic and study
variables
Physical and mental component




Disability Status Scale, SD
standard deviation, ns not
significant. #t-tests; a difference
of proportion test
Parkinson’s disease Multiple sclerosis p/95 % CI
Number of subjects (%) 142 (41.8) 198 (58.2)
Gender
Males (%) 73 (51.4) 64 (32.3) .09; .29a
Females (%) 69 (48.6) 134 (67.7) -.29; -.09a
Mean age in years (SD) 67.6 (9.2) 38.4 (10.8) p B 0.001#
Married or living with a partner (%) 96 (67.6) 121 (61.1) -.03; .17 nsa
Education
Elementary (%) 47 (33.1) 11 (5.6) .19; .36a
Secondary (%) 79 (55.6) 152 (76.8) -.31; -.11a
University (%) 16 (11.3) 35 (17.7) -.14; .01 nsa
Disease duration (SD) 7.6 (5.9) 2.6 (0.8) p B 0.001#
UPDRS (SD) 36.9 (20.2) – –
EDSS (SD) – 3.0 (1.5) –
Clinical course of MS
Relapsing-remitting (%) – 139 (70.2) –
Secondary progressive (%) – 27 (13.6) –
Primary progressive (%) – 29 (14.6) –
Personality
Negative affectivity (SD) 13.2 (6.3) 12.1 (6.3) ns#
Social inhibition (SD) 13.5 (6.2) 12.0 (6.3) p B 0.05#
Type D (%) 75 (52.8) 89 (44.5) -.03; .18 nsa
Depression (SD) 6.6 (3.6) 4.4 (3.5) p B 0.001#
Anxiety (SD) 8.2 (3.9) 7.2 (4.2) p B 0.05#
Physical component summary (SD) 31.4 (11.2) 36.1 (10.8) p B 0.001#
Mental component summary (SD) 43.4 (9.7) 45.8 (9.5) p B 0.05#
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Factors associated with a worse perception of PCS in PD
patients were disease severity, Type D personality and high
anxiety. In MS patients, longer anxiety and disease dura-
tion were predictors of worse MCS (Table 2).
Discussion
Our findings demonstrate a significant association between
Type D personality and the mental health status of both PD
patients and MS patients. However, this association dis-
appeared in the MCS dimension in both diseases, and its
predictive value remained only in the PCS dimension in PD
patients when the variables anxiety and depression were
added to the model. Higher scores in anxiety and depres-
sion were strongly associated with QoL in both diseases.
We might suppose that the actual mood status influences a
patient’s perception of QoL significantly more than per-
sonality traits, which over time are mostly seen as rela-
tively stable. Actual feelings of sadness and fear are
related, with MS and PD patients both reporting worse
QoL. Similar results were found in inflammatory bowel
disease patients, where regression analysis showed that
disease activity and psychological distress were the stron-
gest predictors of QoL impairment and that personality
traits did not play a significant role in QoL [45].
The predictive value of Type D disappeared in Model 3,
although there is no doubt that its importance on QoL
exists. In a previous study, the association between Type D,
its subscales and QoL was explored in patients with PD
[32], and other studies have reported similar results
[31, 33]. Thus, an important question is how personality fits
into the final model consisting, besides personality, also of
mood variables determining QoL in chronically ill patients.
A possible answer might be that personality traits are
associated indirectly with QoL via another variable. Mood
variables mediating the relationship from personality to
QoL was recently suggested by Bartels et al. [33] in the
field of tinnitus. The authors in that study presented a
model in which Type D personality on QoL is mediated by
anxiety and depression in patients with tinnitus. A similar
model could be assumed for other diseases, as PD or MS.
Also, coping style has been proposed as an important
mediating factor with regard to adaptation to illness [17,
46–48]. Patients who more frequently used the emotional
coping style reported being more disabled by their disease
and suffering from poorer mental health and quality of life
[49–51]. A higher level of neuroticism and a low level of
extroversion were found to be related to the emotion-
focused coping strategy of MS patients [52]. Also, in a
sample of young adults suffering from headache, those
reporting lower levels of active pain-coping showed the
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emphasized that being informed about coping strategies
and their relationship to aspects of quality of life in patients
with chronic diseases is important in order to establish
health care interventions aimed to enhance coping skills.
Strengths and limitations
The study’s main strength is its comparison of the two chronic
neurological diseases from, to our knowledge, a new point of
view. The results of this study could be helpful for under-
standing the complexity of QoL, and its factors in patients with
chronic progressive neurological diseases. One of the limita-
tions of the study is its cross-sectional design, which does not
provide us with information about changes to the patient over
time, and thus does not enable us to compare pathways. The
low response rate might also have an impact on generalization
of the results to the total population of PD and MS patients.
Regrettably, we have no information about the disease dura-
tion and disease severity of non-respondents. However, it
might be supposed that they refused to participate in the study
because of serious motor complications found in the higher
stages of PD and MS and due to the need for help from their
social surroundings. Structural equation modeling (SEM)
could also be used as a method of analyzing data in further
research, as it could increase the power of the models.
Implications
Identification of the mechanisms and consequences of
functioning health perception in chronically ill patients is
still a big challenge for further research. Research on QoL
in patients with MS and PD should in further studies
incorporate personality as an integral part of the explana-
tory models of quality of life; next, the relationship
between mood status or psychological distress, personality
traits and QoL should be explored, as well as other psy-
chological factors that could contribute to clarify the
pathways of the variables predicting quality of life of
patients with chronic diseases [53]. For neurological
practice, the study outcomes suggest that good treatment of
mood disorders could substantially contribute to a better
quality of life.
Our findings have clinical relevance, especially for the
process of assessing the severity of symptoms presented by
patients. The validity of information about a patient’s well-
being or health status could be distorted by his or her actual
mood and in patients with Parkinson’s disease also by his or
her personality, especially regarding the physical dimension.
Therefore, patients with Type D personality could report a
worse experiencing of physical well-being or health status in
general. Finally, our outcomes suggest that good treatment
of mood disorders could substantially contribute to a better
quality of life.
Although the results of the study show a relationship
between anxiety, depression and Type D personality, the
physical symptoms of PD or MS may also lead to a worse
experiencing of negative emotions. The direction of the
impact of variables on each other could thus be better
explained by a long-term prospective study in further
research.
Conclusion
Our findings show that actual mood status of MS and PD
patients could be more important than their personality
traits in assessment of QoL. Completing the model and to
clarify the pathway predicting QoL, which could explain
most of the variance of QoL in chronically ill patients, is a
great challenge for further research. A similar model could
have great meaning for clinicians, enabling them to modify
their treatment style such that each patient can benefit
optimally from it.
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